512O Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies
2021
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI